Meeting
2013 Genitourinary Cancers Symposium
Safety profile of poxviral vaccines: NCI experience.
Authors
Joseph W. Kim
Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute, Bethesda, MD
Joseph W. Kim , Jennifer L. Marte , Marijo Bilusic , Nishith K. Singh , Christopher Ryan Heery , Ravi Amrit Madan , Mary Pazdur , Sheri McMahon , Myrna Rauckhorst , Jeffrey Schlom , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00060528, NCT00096551, NCT00088413, NCT00081848, NCT00113984, NCT00450619, NCT00450463
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 85)
DOI
10.1200/jco.2013.31.6_suppl.85
Abstract #
85
Poster Bd #
F4
Abstract Disclosures
Similar Posters
First Author: Snehal Patel
Poster
2022 ASCO Annual Meeting
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Koral Shah
Poster
2021 Genitourinary Cancers Symposium
Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.
First Author: Hiroji Uemura
Poster
2020 ASCO Virtual Scientific Program
A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).
First Author: Roisin Eilish O'Cearbhaill